Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
07 Novembro 2023 - 6:30PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced the appointment of Dr. R. Ananthanarayanan (Ananth) as
CEO of its Teva Active Pharmaceutical Ingredients business (Teva
api). Dr. Ananth will lead the API business starting November 27,
2023, and will be based out of Teva's U.S. headquarters in
Parsippany, NJ.
Richard Francis, Teva’s President and CEO said: “I am excited to
welcome Ananth back to Teva to lead the Teva api business during
this pivotal time for our company, as we continue to progress on
our plan for turning Teva api into a standalone business. We’re
confident that this strategy will result in a more focused
end-to-end operation, and I am confident that Ananth's extensive
knowledge of both Teva and the industry landscape will be an
invaluable asset to drive growth, maximize current and potential
revenue streams, and better serve customers and patients."
Dr. Ananth joins Teva with over 34 years of experience leading
global API businesses in external sales, internal operations and in
contract development and manufacturing operations. He will lead
Teva api through its transformation to a standalone business, which
plays a critical part in Teva's Pivot to Growth strategy announced
in May 2023. Having led the former Teva api and Biologics
Operations organization at Teva from 2014 to 2018, Dr. Ananth has a
deep understanding of Teva’s API business.
Prior to joining Teva, Dr. Ananth previously served as Chief
Executive Officer of a portfolio company of a global leading
private equity firm, and a leading Contract Development and
Manufacturing Organization (CDMO) for large scale production of
Active Ingredients (Agro), electronic chemicals, specialty
chemicals and intermediates for agro, pharma, dyes & pigments.
Prior to this, he served as Chief Executive Officer of Strides
Pharma Science Limited, a global generic pharmaceutical company,
and as Chief Operating Officer at Cipla Limited. Earlier in his
career, Ananth held various leadership positions leading
operations, business development and P&L in the global
pharmaceutical industry including at Piramal and Dr Reddy’s
Laboratories Limited.
Dr. Ananth stated, “I am very excited to return to Teva to lead
the API business, and to join my esteemed colleagues and teams at
Teva api – old and new. I have confidence in the strategic vision
set out by Richard Francis and the Teva executive leadership team
to create a more focused end-to-end operation poised to return to
growth and create more impact and value for Teva and the patients
we serve worldwide."
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
innovative medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative medicines research and
operations supporting our growing portfolio of innovative medicines
and biopharmaceutical products.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to: our ability to successfully
launch and execute our new Pivot to Growth strategy including to
expand our innovative and biosimilar medicines pipeline and
profitably commercialize the innovative medicines and biosimilar
portfolio, whether organically or through business development, to
sustain and focus our portfolio of generics medicines and to turn
our Teva API business into a stand-alone unit; our ability to
attract, hire, integrate and retain highly skilled personnel; our
substantial indebtedness; our business and operations in general,
including: the impact of global economic conditions and other
macroeconomic developments and the governmental and societal
responses thereto; compliance, regulatory and litigation matters,
including: failure to comply with complex legal and regulatory
environments; other financial and economic risks; and other factors
discussed in this press release, in our Quarterly Report on Form
10-Q for the second quarter of 2023 and in our Annual Report on
Form 10-K for the year ended December 31, 2022, including in the
sections captioned "Risk Factors” and “Forward Looking Statements.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107409956/en/
IR Contacts
United States Ran Meir (267) 468-4475
Israel Yael Ashman 972 (3) 914-8262
PR Contacts
United States Kelley Dougherty (973) 658-0237
Israel Eden Klein 972 (3) 906-2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024